Avail Medsystems: Telemedicine Drives Sales Model Efficiency on Path to Digital Surgery

article image

COVID catalyzed procedural telemedicine pioneer Avail’s efforts to improve efficiencies in both medtech sales and medical education through its remote technology system. In the process, the company has attracted significant tech investors, raising a $100 million Series B round over Zoom and turning what was a slower growth area into a red-hot space. Part 1 of a 2-part feature.

When John Adams said, “Every problem is an opportunity in disguise,” he was probably not thinking in terms of a global pandemic. Yet, for Avail Medsystems Inc., that has been the impact of COVID-19. While most medtech companies have struggled with the effects of elective surgical procedures being suspended and in-person access to hospitals, physicians, and other customers restricted largely to remote contact, for Avail, which is pioneering what the company calls “procedural telemedicine,” the changes triggered by the pandemic proved to be a boon for its strategy that could never have been anticipated or otherwise achieved.


This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Sign up for All-Access

Join our global community with a subscription to both MedTech Strategist and Market Pathways for one low price.



We're here to help! Please contact us at: